NEW: Read eCOA Best Practices by Major Pharma Leaders     Download Now

ERT has a full-suite of Clinical Outcome Assessment (COA) solutions to electronically capture patient data directly from the patient, caregiver, and/or their clinician. Our products range from dedicated mobile devices used several times daily, site-based devices used in the physician’s office, to BYOD options (native smartphone apps, IVRS, and Web-based applications) that can be used in any environment.

eCOA-Solutions

ERT’s products have been developed utilizing deep scientific and regulatory expertise. With over 2,000 projects in 75+ countries and 100+ languages and dialects, ERT’s experience is unrivaled.

We have captured eCOA data for 50 global drug and product approvals

Why Capture COA Data Electronically?

In a word – quality! While paper diaries have been used for decades, the advent of technology has allowed us to significantly improve the overall quality of data that we capture from patients, clinicians, and observers/caretakers. Over a decade ago, ERT conducted research to compare patient compliance with paper and electronic diaries. We expected compliance with paper diaries to be lower, but we were shocked by just how low it was. To learn more about this research, read about the study that was published in the British Medical Journal (BMJ). Additionally, data from paper diaries is compromised due to illegibility, skipped responses, and illogical responses (e.g. selecting conflicting responses in a multiple choice selection).

Once patients complete the paper diary, all the data has to be transcribed into an electronic system so the data can be analyzed. This is a time consuming task that also introduces the possibility of transcription errors and adds cost for data entry. All of this slows the time it takes to get to database lock. To learn more about the benefits of eCOA over paper from the sponsor perspective, read the peer-reviewed article, “Proving the eDiary Dividend”.

Why Capture COA Data Electronically?

Over a decade ago, ERT conducted research to compare patient compliance with paper and electronic diaries. We expected compliance with paper diaries to be lower, but we were shocked by just how low it was. Additionally, data from paper diaries is compromised due to illegibility, skipped responses, and illogical responses (e.g. selecting conflicting responses in a multiple choice selection). All the data has to be transcribed into an electronic system so the data can be analyzed, a time consuming task that also introduces the possibility of transcription errors and adds cost for data entry. Learn more about the benefits of eCOA over paper from the sponsor perspective, read the peer-reviewed article, “Proving the eDiary Dividend”.

NEW: Read more on ERT Technology behind eCOA Modalities     Download Now

NEW: Read Scientific Evidence for Successful eCOA use by Elderly Patients     Download Now

eCOA PRO ePRO

UsingePRO1stTime

Why ERT for eCOA?

Service Flexibility

ERT makes customized solutions to fit our customers’ needs by creating a personalized experience with dedicated project and program management teams.

Global Support

Our customers have stressed how important it is to properly support their global trials and that ERT’s execution in this area is the industry’s best. ERT has extensive experience deploying eCOA studies globally in more than 1,200 projects in 75+ countries and 100+ languages and dialects.

Regulatory Expertise

ERT has collected data used in at least 50 successful drug approvals – more than any other eCOA vendor.  With ERT’s extensive knowledge of the FDA’s Guidance for Industry on Patient Reported Outcome Measures and its expansion to cover all COAs, you can be confident that ERT’s eCOA solutions will meet all regulatory requirements.

eCOA PRO ePRO

UsingePRO1stTime

Why ERT for eCOA?

Service Flexibility

ERT makes customized solutions to fit our customers’ needs by creating a personalized experience with dedicated project and program management teams.

Global Support

Our customers have stressed how important it is to properly support their global trials and that ERT’s execution in this area is the industry’s best. ERT has extensive experience deploying eCOA studies globally in more than 1,200 projects in 75+ countries and 100+ languages and dialects.

Regulatory Expertise

ERT has collected data used in at least 50 successful drug approvals – more than any other eCOA vendor.  With ERT’s extensive knowledge of the FDA’s Guidance for Industry on Patient Reported Outcome Measures and its expansion to cover all COAs, you can be confident that ERT’s eCOA solutions will meet all regulatory requirements.

eCOA-Solutions

eCOA.CTA-WCF1

WANT TO LEARN MORE?